Answers are grounded in this paper and cite their sources.
Bispecific antibodies are unique in the sense that they can bind simultaneously two different antigens. This property enables the development of therapeutic strategies that are not possible with conventional monoclonal antibodies. The large panel of imaginative bispecific antibody formats that has been developed reflects the strong interest for these molecules. Although in many cases the manufacturing of clinical grade material remains challenging, several bispecific antibody formats are currently in clinical trials.
No takes yet. Share an insight, caveat, or question.
Fischer et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: